Clinical Trials Logo

Multiple Myeloma, Refractory clinical trials

View clinical trials related to Multiple Myeloma, Refractory.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT05191472 Terminated - Multiple Myeloma Clinical Trials

Pembrolizumab for the Treatment of Relapsed or Refractory Multiple Myeloma After Anti-BCMA CAR-T Therapies

Start date: May 3, 2022
Phase: Phase 2
Study type: Interventional

This phase II trial tests whether pembrolizumab works to shrink tumors in patients with multiple myeloma whose cancer has come back (relapsed) or did not respond to previous treatment (refractory) with anti-BCMA CAR-T therapies. Immunotherapy with pembrolizumab, may induce changes in body's immune system and may interfere with the ability of cancer cells to grow and spread.